-
In January 2025, Abbott launched a new lateral flow assay for rapid HIV detection, focusing on low-resource settings in Africa and Asia. This high-sensitivity test delivers quick and reliable results, enhancing early diagnosis and treatment accessibility. Designed for cost-effectiveness, it supports widespread adoption in community healthcare programs. The innovation strengthens Abbott’s presence in the global point-of-care (POC) market, reinforcing its commitment to affordable and scalable diagnostic solutions
- In March 2024, bioMérieux secured U.S. FDA clearance and a CLIA waiver for its BIOFIRE SPOTFIRE Respiratory/Sore Throat (R/ST) Panel, reinforcing its leadership in respiratory infection diagnostics. This multiplex PCR test detects up to 15 common pathogens in about 15 minutes, enabling rapid and accurate diagnoses. The approval enhances bioMérieux’s competitive edge, allowing broader clinical adoption in urgent care, pharmacies, and outpatient settings. By streamlining syndromic testing, the panel supports antimicrobial stewardship and modernized patient care
- In January 2024, Roche acquired LumiraDx’s point-of-care technology, integrating its advanced immunoassay and clinical chemistry platform into its diagnostics portfolio. This acquisition enhances Roche’s capabilities in decentralized patient care, expanding access to rapid and accurate testing in primary care settings. LumiraDx’s multi-assay system consolidates various tests on a single instrument, streamlining workflows and improving diagnostic efficiency. Roche aims to leverage this technology to advance molecular testing, supporting global healthcare accessibility
- In February 2023, Thermo Fisher Scientific partnered with Mylab Discovery Solutions to introduce made-in-India RT-PCR kits for infectious disease diagnostics. This collaboration enhances accessibility and affordability, targeting a broader population in India and globally. The kits, licensed by CDSCO, support rapid and accurate detection of tuberculosis, hepatitis, HIV, and other diseases. By leveraging advanced molecular diagnostics, the partnership aims to strengthen healthcare infrastructure and meet disease elimination targets
- In November 2022, LumiraDx Healthcare introduced its highly sensitive C-Reactive Protein (CRP) point-of-care antigen test across India, aiming to combat antimicrobial resistance (AMR). This rapid diagnostic tool delivers results within four minutes using a finger-prick blood sample, enabling clinicians to make informed antibiotic decisions. By reducing unnecessary prescriptions, the test supports AMR stewardship programs and enhances patient care in ICUs, pediatric departments, emergency rooms, and outpatient clinics. The launch aligns with India’s healthcare priorities, ensuring effective infection management
